Jason Coloma, Maze Therapeutics CEO
Updated: Maze reveals positive first look at PhI Pompe disease candidate
The scientists at Maze Therapeutics call themselves “genetic navigators,” and on Thursday, they mapped out some positive Phase I results from their most advanced program …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.